Acelyrin says goodbye to the drug that got it a $540M IPO in 2023
Acelyrin is officially ending development of an experimental medicine it referred to as a “diamond in the rough” and that served as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
